Acumen Pharmaceuticals Sets Virtual Investor Day for September 16, 2026 — Acumen Pharmaceuticals, Inc.

Event summary

Acumen Pharmaceuticals will host a virtual Investor Day on September 16, 2026, at 10:00 a.m. ET.
The event follows positive Phase 1 trial results for its lead candidate, sabirnetug (ACU193).
Acumen is advancing sabirnetug in a Phase 2 trial (ALTITUDE-AD) for early symptomatic Alzheimer’s disease.
The company is also developing a subcutaneous formulation of sabirnetug using Halozyme’s ENHANZE® technology.
Acumen is collaborating with JCR Pharmaceuticals on an Enhanced Brain Delivery™ therapy.

The big picture

Acumen Pharmaceuticals’ Investor Day comes at a critical juncture as it advances its lead candidate, sabirnetug, through Phase 2 trials. The company’s focus on targeting toxic soluble amyloid beta oligomers aligns with growing evidence of their role in Alzheimer’s disease pathology. Strategic partnerships with Halozyme and JCR Pharmaceuticals could enhance its drug delivery capabilities and market positioning in a highly competitive sector.

What we're watching

Clinical Progress: How the Phase 2 trial results for sabirnetug will impact Acumen’s valuation and investor confidence.
Partnership Dynamics: Whether the collaborations with Halozyme and JCR Pharmaceuticals will accelerate development timelines.
Market Positioning: The pace at which Acumen can differentiate itself in the competitive Alzheimer’s disease treatment landscape.